Conversely, the heterozygous genotype FASL-844 TC conferred lower risk for CML susceptibility (OR 0.379, CI 0.176-0.816, p=0.013). This evidence concerns the gene FASLG and chronic myelogenous leukemia, BCR-ABL1 positive.